“Personalized medicines have the potential to innovate how a treatment can address specific traits of a disease in a patient and give them a better quality of life. That is truly a remarkable endeavor, and the Heidelberg site is proud to have this opportunity to help NEC Bio Therapeutics on its mission of combining AI and machine learning with traditional biologics and personalized care,” said Dieter Kramer, General Manager, AGC Biologics Heidelberg. “We are eager to begin work and to collaborate with our new partners on this important journey.”